Cliff Asness’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.58B Sell
27,357,486
-2,273,619
-8% -$131M 0.55% 13
2026
Q1
$1.8B Buy
29,631,105
+3,834,200
+15% +$224M 0.82% 6
2025
Q4
$1.39B Buy
25,796,905
+16,332,924
+173% +$786M 0.73% 8
2025
Q3
$426M Buy
9,463,981
+3,396,041
+56% +$159M 0.27% 66
2025
Q2
$281M Buy
6,067,940
+98,910
+2% +$4.86M 0.23% 92
2025
Q1
$364M Buy
5,969,030
+1,962,233
+49% +$114M 0.38% 45
2024
Q4
$227M Buy
4,006,797
+106,630
+3% +$5.96M 0.29% 59
2024
Q3
$200M Buy
3,900,167
+1,223,871
+46% +$57.4M 0.28% 68
2024
Q2
$111M Buy
2,676,296
+327,824
+14% +$14.7M 0.17% 149
2024
Q1
$126M Buy
2,348,472
+246,701
+12% +$12.6M 0.22% 113
2023
Q4
$108M Sell
2,101,771
-153,229
-7% -$8.04M 0.2% 113
2023
Q3
$131M Sell
2,255,000
-654,731
-23% -$40.1M 0.27% 77
2023
Q2
$186M Buy
2,909,731
+168,024
+6% +$11.3M 0.4% 47
2023
Q1
$189M Buy
2,741,707
+511,072
+23% +$36M 0.42% 43
2022
Q4
$160M Buy
2,230,635
+598,538
+37% +$45.1M 0.36% 49
2022
Q3
$116M Buy
1,632,097
+66,803
+4% +$4.85M 0.28% 75
2022
Q2
$120M Buy
1,565,294
+119,402
+8% +$9.09M 0.27% 75
2022
Q1
$106M Sell
1,445,892
-79,802
-5% -$5.36M 0.2% 112
2021
Q4
$95.1M Sell
1,525,694
-31,691
-2% -$1.86M 0.17% 136
2021
Q3
$92.2M Sell
1,557,385
-454,820
-23% -$30M 0.17% 144
2021
Q2
$134M Sell
2,012,205
-738,957
-27% -$48.2M 0.23% 102
2021
Q1
$173M Sell
2,751,162
-80,939
-3% -$5.04M 0.28% 74
2020
Q4
$173M Sell
2,832,101
-391,849
-12% -$24.1M 0.31% 65
2020
Q3
$193M Sell
3,223,950
-184,333
-5% -$11.1M 0.33% 60
2020
Q2
$196M Sell
3,408,283
-625,065
-15% -$37.4M 0.32% 69
2020
Q1
$223M Buy
4,033,348
+363,125
+10% +$22.2M 0.38% 61
2019
Q4
$234M Buy
3,670,223
+633,429
+21% +$36.3M 0.27% 100
2019
Q3
$154M Sell
3,036,794
-4,643,327
-60% -$218M 0.18% 146
2019
Q2
$347M Sell
7,680,121
-820,972
-10% -$38.2M 0.39% 55
2019
Q1
$400M Sell
8,501,093
-18,893
-0.2% -$941K 0.42% 49
2018
Q4
$443M Buy
8,519,986
+2,298,527
+37% +$123M 0.51% 42
2018
Q3
$386M Buy
6,221,459
+1,013,134
+19% +$60.1M 0.37% 63
2018
Q2
$288M Buy
5,208,325
+1,865,193
+56% +$101M 0.29% 84
2018
Q1
$211M Sell
3,343,132
-729,867
-18% -$47M 0.23% 106
2017
Q4
$250M Buy
4,072,999
+988,731
+32% +$61.8M 0.26% 101
2017
Q3
$197M Buy
3,084,268
+832,608
+37% +$48.6M 0.23% 107
2017
Q2
$125M Buy
2,251,660
+1,772,855
+370% +$96.5M 0.17% 166
2017
Q1
$26M Buy
478,805
+69,477
+17% +$3.81M 0.03% 535
2016
Q4
$23.9M Sell
409,328
-405,756
-50% -$22.2M 0.03% 558
2016
Q3
$43.9M Buy
815,084
+201,613
+33% +$13M 0.07% 392
2016
Q2
$45.1M Sell
613,471
-204,936
-25% -$14.5M 0.08% 344
2016
Q1
$52.3M Sell
818,407
-376,506
-32% -$23.7M 0.09% 295
2015
Q4
$82.2M Sell
1,194,913
-761,854
-39% -$50.3M 0.14% 193
2015
Q3
$116M Buy
1,956,767
+593,640
+44% +$37.7M 0.23% 114
2015
Q2
$90.7M Buy
1,363,127
+888,048
+187% +$58.5M 0.18% 159
2015
Q1
$30.6M Buy
475,079
+53,300
+13% +$3.34M 0.07% 310
2014
Q4
$24.9M Sell
421,779
-713,475
-63% -$40.2M 0.05% 421
2014
Q3
$58.1M Buy
1,135,254
+137,868
+14% +$6.89M 0.16% 167
2014
Q2
$48.4M Buy
997,386
+422,926
+74% +$20.8M 0.13% 211
2014
Q1
$29.8M Buy
574,460
+90,445
+19% +$4.81M 0.09% 269
2013
Q4
$25.7M Buy
484,015
+152,821
+46% +$7.78M 0.08% 314
2013
Q3
$15.3M Buy
331,194
+1,793
+0.5% +$78.7K 0.05% 419
2013
Q2
$14.7M Buy
+329,401
New +$14.3M 0.05% 436

Other funds holding BMY

Cliff Asness's BMY Position: Q2 2026 in Review

Cliff Asness reduced its Bristol-Myers Squibb (BMY) stake by 7.7% in Q2 2026, selling an estimated $131M and leaving 27,357,486 shares worth $1.58B. The position accounts for 0.55% of the portfolio, ranked #13.

Cliff Asness first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.8B in Q1 2026. 2,506 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Cliff Asness held 27,357,486 shares of Bristol-Myers Squibb worth $1.58B as of Q2 2026.
  • Cliff Asness sold 2,273,619 Bristol-Myers Squibb shares in Q2 2026, an estimated $131M.
  • Bristol-Myers Squibb made up 0.55% of Cliff Asness's portfolio in Q2 2026, its #13 holding.
  • Cliff Asness first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Cliff Asness's Bristol-Myers Squibb position peaked at $1.8B in Q1 2026.
  • 2,506 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.